AMRX Q4 2021 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q4 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$537M+5.3% YoY

Gross Profit

$166M31.0% margin

Operating Income

$11M2.1% margin

Net Income

-$6M-1.2% margin

EPS (Diluted)

$-0.04

QoQ Revenue Growth

+1.6%

Cash Flow

Operating Cash Flow

$63M

Free Cash Flow

$45M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$3.9B

Total Liabilities

$3.6B

Stockholders' Equity

$360M

Cash & Equivalents

$248M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$537M	$510M	+5.3%
Gross Profit	$166M	$167M	-0.4%
Operating Income	$11M	$20M	-44.6%
Net Income	-$6M	-$3M	-110.0%

Revenue Segments

Generics Segment

$346M77%

Amneal Specialty Pharma Segment

$101M23%